Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III docetaxel dosing schedule trial in metastatic hormone-refractory prostate cancer
2004-004295-37Phase 3Completed
- Sponsor
- Finnish Uro-Oncological Group
- Start
- Jul 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Finnish Uro-Oncological Group. Primary endpoint: Time to treatment failure. Started Jul 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2004-004295-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004295-37.